All In Biotech

Drug Trial Radar · NCT04950127

Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)

A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)

Last checked: Nov 20, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 238 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

238

Actual

Start

Aug 27, 2021

Primary completion

Oct 28, 2024

Study completion Dec 20, 2024

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 6, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.

Conditions

  • Pruritus

Interventions

  • LinerixibatDrug

    Participants will receive linerixibat.

  • PlaceboDrug

    Participants will receive placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Mean Change From Baseline in Monthly Itch Scores Over 24 Weeks Using Numerical Rating Scale (NRS)Time frame: Baseline and up to Week 24

Locations

5 sites in 2 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Erlangen, Germany

  • GSK Investigational Site

    Münster, Germany

  • GSK Investigational Site

    Cambridge, United Kingdom

  • GSK Investigational Site

    Durham, United Kingdom

  • GSK Investigational Site

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.